Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results

OBJECTIVE: Since 2014, cannabidiol (CBD) has been administered to patients with treatment‐resistant epilepsies (TREs) in an ongoing expanded‐access program (EAP). We report interim results on the safety and efficacy of CBD in EAP patients treated through December 2016. METHODS: Twenty‐five US‐based...

Descripción completa

Detalles Bibliográficos
Autores principales: Szaflarski, Jerzy P., Bebin, Elizabeth Martina, Comi, Anne M., Patel, Anup D., Joshi, Charuta, Checketts, Daniel, Beal, Jules C., Laux, Linda C., De Boer, Lisa M., Wong, Matthew H., Lopez, Merrick, Devinsky, Orrin, Lyons, Paul D., Zentil, Pilar Pichon, Wechsler, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Full‐length Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175436/
https://www.ncbi.nlm.nih.gov/pubmed/29998598
http://dx.doi.org/10.1111/epi.14477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175436/
https://www.ncbi.nlm.nih.gov/pubmed/29998598
http://dx.doi.org/10.1111/epi.14477

Ejemplares similares